DOCSLIB.ORG

WO 2013/138666 Al I

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WO 2013/138666 Al I (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2013/138666 Al 19 September 2013 (19.09.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07C 279/04 (2006.01) A61P 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/165 (2006.01) A61P 35/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2013/031737 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 March 2013 (14.03.2013) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/61 1,967 16 March 2012 (16.03.2012) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: SANFORD-BURNHAM MEDICAL RE¬ GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, SEARCH INSTITUTE [US/US]; 10901 North Torrey UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Pines Road, La Jolla, CA 92037 (US). TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (72) Inventor; and MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (71) Applicant (for US only): STRONGIN, Alex [US/US]; TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 10901 North Torrey Pines Road, La Jolla, CA 92037 (US). ML, MR, NE, SN, TD, TG). (72) Inventors: PELLECCHIA, Maurizio; 10901 North Tor Published: rey Pines Road, La Jolla, CA 92037 (US). BARILE, Elisa; 10901 North Torrey Pines Road, La Jolla, CA 92037 (US). — with international search report (Art. 21(3)) (74) Agent: HOSTETLER, Michael, J.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304 (US). (54) Title: INHIBITORS OF FURIN AND OTHER PRO-PROTEIN CONVERTASES / 96B22 I i' «°- 7 96B23 6 -4 -2 0 Log [inhibitor] µ 96B22 96B23 00 HiliSlope 1.622 | 1.068 IC50 0,003686 j 0,009096 (57) Abstract: Disclosed herein are Furin/PC inhibitors for inhibiting Furin and other Propprotein Convertases. Method of making the Furin/PC inhibitors, chemical and biological characterization of the Furin/PC inhibitors, and the use of the Furin/PC inhibitors to o treat infectious diseases, cancers, and inflammatory/autoimmune disorders, are also disclosed. INHIBITORS OF FURIN AND OTHER PRO-PROTEIN CONVERTASES CROSS-REFERENCE [0001] The present application claims benefit of U.S. Provisional Application No. 61/61 1,967, filed on March 16, 2012, which is incorporated herein by reference in its entirety. BACKGROUND [0002] Furin belongs to the subtilisin-like proprotein convertase family. Furin is a proprotein convertase that processes latent precursor proteins into their biologically active products. It is a calcium-dependent serine endoprotease that cleaves precursor proteins at their paired basic amino acid processing sites. Some of the Furin substrates are: proparathyroid hormone, transforming growth factor beta 1 precursor, prealbumin, pro-beta-secretase, membrane type-1 matrix metalloproteinase, beta subunit of pro-nerve growth factor and von Willebrand factor. SUMMARY OF THE DISCLOSURE [0003] Disclosed herein, in certain embodiments, are compounds having the general structure I or pharmaceutically acceptable salts thereof: A compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof: wherein R is alkyl, cycloalkyl, heteroalicyclyl, aryl, or heteroaryl; R2 is alkyl, cycloalkyl, or heteroalicyclyl; R is -Z-guanidine or -Z-C(NH 2)=NH, wherein Z is aryl or heteroaryl; is -W-C(NH 2)=NR', wherein W is aryl, thiophenyl, furanyl, oxazolyl, pyrrolyl, or picolinyl; and wherein R' is hydrogen or hydroxyl; R5 is -U-guanidine, wherein U is alkyl, cycloalkyl, heteroalicyclyl, aryl, or heteroaryl; X= -C¾-, -CH2-CH2-, -CH2NHC(=0)-, -CH2CH2C(=0)NH-, or -CH2C(=0)NH-; Y is -CH 2-,-S(=0) 2-, or -C(=0)-. In some embodiments of the compound of Formula I, R' is hydrogen. In some embodiments of the compound of Formula I, R' is hydroxyl. In some embodiments of the compound of Formula I, i is a CrC 6 alkyl. In some embodiments of the compound of Formula I, R1 is methyl. In some embodiments of the compound of Formula I, R2 is a Ci-C^ alkyl. In some embodiments of the compound of Formula I, R2 is isopropyl. In some embodiments of the compound of Formula I, U is Ci-Ce alkyl. In some embodiments of the compound of Formula I, U is -(CH 2)3-. In some embodiments of the compound of Formula I, X is -CH2-. In some embodiments of the compound of Formula I, R is -Z-guanidine. In some embodiments of the compound of Formula I, Z is In some embodiments of the compound of Formula I, X is -CH2- and R In some embodiments of the compound of Formula I, Y is -CH 2-. In some embodiments of the compound of Formula I, W ; R is -F, -CF3, -OCF , -OCH3, or alkyl; and n is 0, 1, or 2. In a refinement, R7 is -F. In a further refinement, n is 1. In some embodiments, the compound of Formula I is selected from the rou consisting of: [0004] Further disclosed herein, in certain embodiments, are compounds of Formula II, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof: wherein: is alkyl, cycloalkyl, or heteroalicyclyl; R2 is -U-guanidine, wherein U is alkyl, cycloalkyl, heteroalicyclyl, aryl, or heteroaryl; Y is -CONH-, -SO2NH-, -0-, -CH2-, -S-, -S0 2-, or -COS0 2NH-; Z is -CONH-, -SO2NH-, -0-, -CH2-, -S-, -S0 2-, or -COS0 2NH-; R3 and are each independently -F, -CF3, -OCF3, -OCH3, or alkyl; a and b are each independently 0, 1, or 2; and m and n are each independently 0, 1, , or 3. In some embodiments of the compound of Formula II, R i is Ci-C alkyl. In some embodiments of the compound of Formula Π, is isopropyl. In some embodiments of the compound of Formula II, U is - alkyl. In some embodiments of the compound of Formula II, U is -(CH 2)3-. In some embodiments of the compound of Formula II, Y is -CONH-. In some embodiments of the compound of Formula II, Z is -SO2NH-. In some embodiments of the compound of Formula II, m is 1 and n is 1. In some embodiments of the compound of Formula II, a and b are 0. In some embodiments, the compound of Formula II [0005] Also disclosed herein, in certain embodiments, are pharmaceutical compositions comprising a Furin/PC inhibitor disclosed herein. [0006] Additionally disclosed herein, in certain embodiments, are methods of treating an infectious disease in a subject in need of such treatment. In some embodiments, the methods comprise administering a therapeutically effective amount of a Furin/PC inhibitor disclosed herein. In some embodiments, the infection disease is associated with influenza virus, human immunodeficiency virus 1, Ebola, measles, cytomegalovirus, and flaviviruses (Dengue, Yellow fever, West Nile, Japanese encephalitis and multiple additional related flaviviruses) and parasitic nemarodes. In some embodiments, the Furin/PC inhibitor neutralizes an esotoxin selected from the group consisting of anthrax toxin, pseudomonas exotoxin A, Shiga toxin, diphtheria toxin, tetanus and botulism neurotoxins, and combinations thereof. In some embodiments, the Furin/PC inhibitor neutralizes virulence of bacteria carrying the esotoxin. [0007] Further disclosed herein, in certain embodiments, are methods of treating a cancer in a subject in need thereof. In some embodiments, the methods comprise administering a therapeutically effective amount of a Furin/PC inhibitor disclosed herein. In some embodiments, the cancer is skin tumors, head and neck squamous cell carcinomas, astrocytoma, lung non-small cell carcinoma, or metastasis of colorectal cancer. [0008] Also disclosed herein, in certain embodiments, are methods of treating an autoimmune or inflammatory disease, disorder or condition in a subject in need thereof. In some embodiments, the methods comprise administering a therapeutically effective amount of a Furin/PC inhibitor disclosed herein. In some embodiments, the autoimmune or inflammatory disease is atherosclerosis, arthritis, or Alzheimer's Disease. BRIEF DESCRIPTION OF THE DRAWINGS [0009] The technical features of the present disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings of which: [00010] FIG. 1 exemplifies the HPLC profile of Compound A; [0001 1] FIG. 2 exemplifies the MS profile of Compound A 2; [00012] FIG. 3 exemplifies the 1H NMR spectrum of Compound A in DMSO-d6; [00013] FIG. 4 exemplifies the HPLC profile Compound B; [00014] FIG. 5 exemplifies the 1H NMR spectrum of Compound B in deuterated PBS; [00015] FIG. 6 exemplifies the MS (MALDI) profile of Compound D; [00016] FIG. 7 exemplifies the HPLC profile of Compound D; [00017] FIG. 8 exemplifies the 1H NMR spectrum of Compound D in deuterated PBS; [00018] FIG.
Load more

Recommended publications
  • Identification of Chalcone Derivatives As Putative Non-Steroidal Aromatase
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Online Publishing @ NISCAIR Indian Journal of Chemistry Vol. 59B, February 2020, pp. 283-293 Identification of chalcone derivatives as putative non-steroidal aromatase inhibitors potentially useful against breast cancer by molecular docking and ADME prediction Umang Shah*a, Samir Patela, Mehul Patela, Karan Gandhia & Ashish Patelb a Department of Pharmaceutical Chemistry, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa 388 421, India b Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Parul University, P.O. Limda 391 760, Dist. Vadodara, India E-mail: [email protected] Received 30 August 2019; accepted (revised) 16 October 2019 Aromatase is an influential target to overcome estrogen receptor positive breast cancer, as the enzyme is responsible for conversion of androstenedione to estrone, a promising drug target for therapeutic management of breast cancer. Chalcones are prominent biosynthetic compounds and parent candidate for the synthesis of heterocycles with diversified biological activities. The prime objective of the present study is to evaluate the binding interaction of 2-hydroxyphenyl- prop-2-en-1- one (1A-1X), 2-hydroxy-4-methoxyphenyl- prop-2-en-1-one (3A-3X), 2,4-dihydroxyphenyl- prop-2-en-1-one (9A-9X) and 1-hydroxynaphthalen-2-yl-prop-2-en-1-one (5A-5X) derivatives with aromatase enzyme by molecular docking study and also check their ADME properties by maestro suit. The designed chalcones derivatives have been docked against our target protein with PDB id 3S7S retrieved from the protein data bank, whereas exemestane has been taken as the positive control.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Syntheses and Biological Activity of Sparsomycin and Analogs
    SYNTHESES AND BIOLOGICAL ACTIVITY OF SPARSOMYCIN AND ANALOGS THE CHEMISTRY OF CHIRAL FUNCTIONALIZED SULFOXIDES AND SULTINES DERIVED FROM CYSTEINE ROB M.J. LISKAMP SYNTHESES AND BIOLOGICAL ACTIVITY OF SPARSOMYCIN AND ANALOGS THE CHEMISTRY OF CHIRAL FUNCTIONALIZED SULFOXIDES AND SULTINES DERIVED FROM CYSTEINE Promotor : Prof. Dr. R.J.F. Nivard Co-referent : Dr. H.C.J. Ottenheijm SYNTHESES AND BIOLOGICAL ACTIVITY OF SPARSOMYCIN AND ANALOGS THE CHEMISTRY OF CHIRAL FUNCTIONALIZED SULFOXIDES AND SULTINES DERIVED FROM CYSTEINE PROEFSCHRIFT TER VERKRIJGING VAN DE GRAAD VAN DOCTOR IN DE WISKUNDE EN NATUURWETENSCHAPPEN AAN DE KATHOLIEKE UNIVERSITEIT VAN NIJMEGEN OP GEZAG VAN DE RECTOR MAGNIFICUS PROF. DR. J.H.G.I. GIESBERS VOLGENS HET BESLUIT VAN HET COLLEGE VAN DEKANEN IN HET OPENBAAR TE VERDEDIGEN OP VRIJDAG 10 DECEMBER 1982 DES NAMIDDAGS OM 4 UUR DOOR ROBERTUS MATTHIAS JOSEPH LISKAMP GEBOREN TE NIJMEGEN NIJMEGEN 1982 Dit proefschrift vormt de neerslag van vier jaar wetenschappelijk onderzoek. Ik wil iedereen - en dat waren er zeer velen - bedanken, die hieraan gedurende die tijd door hun stimulerende discussie of door de feitelijke uitvoering deel hadden. Zij gaven mede richting en vorm, niet alleen organisch maar ook biochemisch/biologisch en fysisch chemisch, aan het verrichte onderzoek. Daarnaast wil ik hen bedanken die een bijdrage geleverd hebben aan de onmis­ bare technische uitvoering van het in dit proefschrift beschreven onderzoek. En tenslotte wil ik ook hen bedanken die aan de vormgeving van het proef­ schrift hun medewerking hebben verleend. Tekeningen : Wim van Luijn en de afdeling illustratie Type-werk : Dorine Hesselink-Balvert Afbeelding op de omslag: Een 'stacked plot' van een 2D-spin-echo correlated spectrum van synthetisch sparsomycine verzorgd door Wim Guijt This research was supported by the Netherlands Foundation for Chemical Research (SON) with financial aid from the Netherlands Organization for the Advancement of Pure Research (ZWO).
    [Show full text]
  • Differences Between the Non-Steroidal Aromatase Inhibitors Anastrozole and Letrozole – of Clinical Importance?
    British Journal of Cancer (2011) 104, 1059 – 1066 & 2011 Cancer Research UK All rights reserved 0007 – 0920/11 www.bjcancer.com Minireview Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance? ,1 J Geisler* 1 Institute of Clinical Medicine, University of Oslo, Faculty Division at Akershus University Hospital, Sykehusveien 27, Lørenskog N-1478, Norway Aromatase inhibition is the gold standard for treatment of early and advanced breast cancer in postmenopausal women suffering from an estrogen receptor-positive disease. The currently established group of anti-aromatase compounds comprises two reversible aromatase inhibitors (anastrozole and letrozole) and on the other hand, the irreversible aromatase inactivator exemestane. Although exemestane is the only widely used aromatase inactivator at this stage, physicians very often have to choose between either anastrozole or letrozole in general practice. These third-generation aromatase inhibitors (letrozole/Femara (Novartis Pharmaceuticals, Basel, Switzerland) and anastrozole/Arimidex (AstraZeneca, Pharmaceuticals, Macclesfield, Cheshire, UK)), have recently demonstrated superior efficacy compared with tamoxifen as initial therapy for early breast cancer improving disease-free survival. However, although anastrozole and letrozole belong to the same pharmacological class of agents (triazoles), an increasing body of evidence suggests that these aromatase inhibitors are not equipotent when given in the clinically established doses. Preclinical and clinical evidence indicates distinct pharmacological profiles. Thus, this review focuses on the differences between the non-steroidal aromatase inhibitors allowing physicians to choose between these compounds based on scientific evidence. Although we are waiting for the important results of a still ongoing head-to-head comparison in patients with early breast cancer at high risk for relapse (Femara Anastrozole Clinical Evaluation trial; ‘FACE-trial’), clinicians have to make their choices today.
    [Show full text]
  • WO 2017/112768 Al 29 June 2017 (29.06.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/112768 Al 29 June 2017 (29.06.2017) P O P C T (51) International Patent Classification: Delaware 19707 (US). ZHUANG, Linghang; 3135 Fox C07D 471/10 (2006.01) A61K 31/47 (2006.01) Drive, Chalfont, Pennsylvania 18914 (US). C07D 487/10 (2006.01) A61K 31/519 (2006.01) (74) Agents: DAVEY, PH.D., Evan A. et al; Fish & Richard C07D 495/04 (2006.01) A61P 35/02 (2006.01) son P.C., P.O. Box 1022, Minneapolis, Minnesota 55440- C07D 513/04 (2006.01) 1022 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US20 16/0680 16 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 2 1 December 2016 (21 .12.2016) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (26) Publication Language: English KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (30) Priority Data: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 62/270,973 22 December 201 5 (22. 12.2015) US RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (71) Applicant: VITAE PHARMACEUTICALS, INC.
    [Show full text]
  • The Ribosomal Peptidyl Transferase Center: Structure, Function, Evolution, Inhibition
    Critical Reviews in Biochemistry and Molecular Biology, 40:285–311, 2005 Copyright c Taylor & Francis Inc. ! ISSN: 1040-9238 print / 1549-7798 online DOI: 10.1080/10409230500326334 The Ribosomal Peptidyl Transferase Center: Structure, Function, Evolution, Inhibition Norbert Polacek Innsbruck Biocenter, Division of ABSTRACT The ribosomal peptidyl transferase center (PTC) resides in the Genomics and RNomics, large ribosomal subunit and catalyzes the two principal chemical reactions of Innsbruck Medical University, protein synthesis: peptide bond formation and peptide release. The catalytic Innsbruck, Austria mechanisms employed and their inhibition by antibiotics have been in the Alexander S. Mankin focus of molecular and structural biologists for decades. With the elucidation Center for Pharmaceutical of atomic structures of the large ribosomal subunit at the dawn of the new Biotechnology, University of millennium, these questions gained a new level of molecular significance. The Illinois at Chicago, Chicago, crystallographic structures compellingly confirmed that peptidyl transferase is IL 60607, USA an RNA enzyme. This places the ribosome on the list of naturally occurring riboyzmes that outlived the transition from the pre-biotic RNA World to con- temporary biology. Biochemical, genetic and structural evidence highlight the role of the ribosome as an entropic catalyst that accelerates peptide bond for- mation primarily by substrate positioning. At the same time, peptide release should more strongly depend on chemical catalysis likely involving an rRNA group of the PTC. The PTC is characterized by the most pronounced accu- mulation of universally conserved rRNA nucleotides in the entire ribosome. Thus, it came as a surprise that recent findings revealed an unexpected high level of variation in the mode of antibiotic binding to the PTC of ribosomes from different organisms.
    [Show full text]
  • Aromatase and Its Inhibitors: Significance for Breast Cancer Therapy † EVAN R
    Aromatase and Its Inhibitors: Significance for Breast Cancer Therapy † EVAN R. SIMPSON* AND MITCH DOWSETT *Prince Henry’s Institute of Medical Research, Monash Medical Centre, Clayton, Victoria 3168, Australia; †Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, United Kingdom ABSTRACT Endocrine adjuvant therapy for breast cancer in recent years has focussed primarily on the use of tamoxifen to inhibit the action of estrogen in the breast. The use of aromatase inhibitors has found much less favor due to poor efficacy and unsustainable side effects. Now, however, the situation is changing rapidly with the introduction of the so-called phase III inhibitors, which display high affinity and specificity towards aromatase. These compounds have been tested in a number of clinical settings and, almost without exception, are proving to be more effective than tamoxifen. They are being approved as first-line therapy for elderly women with advanced disease. In the future, they may well be used not only to treat young, postmenopausal women with early-onset disease but also in the chemoprevention setting. However, since these compounds inhibit the catalytic activity of aromatase, in principle, they will inhibit estrogen biosynthesis in every tissue location of aromatase, leading to fears of bone loss and possibly loss of cognitive function in these younger women. The concept of tissue-specific inhibition of aromatase expression is made possible by the fact that, in postmenopausal women when the ovaries cease to produce estrogen, estrogen functions primarily as a local paracrine and intracrine factor. Furthermore, due to the unique organization of tissue-specific promoters, regulation in each tissue site of expression is controlled by a unique set of regulatory factors.
    [Show full text]
  • Refined Preparation of 1α,3-Dipyrrolidino-Androsta-3,5-Diene-17-One, a Key Intermediate in the Exemestane Synthesis
    ORIGINAL ARTICLES Pharmaceutical Research Institute1; Faculty of Chemistry, University of Warsaw, Warsaw, Poland Refined preparation of 1␣,3-dipyrrolidino-androsta-3,5-diene-17-one, a key intermediate in the exemestane synthesis Ł. Kaczmarek 1, M. Cybulski 1, M. Kubiszewski 1,A.Les´ 1,2 Received February 3, 2012, accepted March 31, 2012 Prof. Andrzej Le´s, Pharmaceutical Research Institute, Rydygiera 8, 01-793 Warsaw, Poland [email protected] Pharmazie 67: 899–905 (2012) doi: 10.1691/ph.2012.2025 A significant improvement of the patent route for exemestane synthesis has been achieved. The key inter- mediate 1␣,3-dipyrrolidino-androsta-3,5-diene-17-one (7) was obtained in a good yield and effectively used without further isolation in the next reaction step. The original analytical method for the identification and quantification of the substrate androsta-1,4-diene-3,17-dione (ADD, 6), intermediate 7 and 1-pyrrolidino- androsta-1,3,5-triene-17-one (9) impurity in the reaction mixture was applied. Due to the newly developed process, the economical synthesis of the final pharmaceutical product in a large scale was possible. In addition, the complete NMR characteristics of 7 was described for the first time. The experiments were also analyzed with the theoretical quantum mechanical density functional B3LYPcalculations for the energy outputs in model reactions. Based on these studies hypothetical routes of key intermediate (7) formation have been suggested. These predictions were consistent with the solutions of kinetic equations fitted to the experimental curves for time-dependence of three components of the reaction mixture. 1.
    [Show full text]
  • TOMMANNUUTTILIMINATIONUS009862693B2 (12 ) United States Patent ( 10 ) Patent No
    TOMMANNUUTTILIMINATIONUS009862693B2 (12 ) United States Patent ( 10 ) Patent No. : US 9 , 862, 693 B2 Pietras et al. (45 ) Date of Patent : Jan . 9 , 2018 ( 54 ) COMPOUNDS AND METHODS OF ( 56 ) References Cited TREATING CANCER U . S . PATENT DOCUMENTS (71 ) Applicant : The Regents of the University of 4 , 574 ,123 A * 3 / 1986 Edwards . .. .. C07C 279/ 28 California , Oakland , CA (US ) 162 / 161 4 , 861, 760 A 8 / 1989 Mazuel et al. ( 72 ) Inventors : Richard J . Pietras , Los Angeles , CA 4 ,911 , 920 A 3 / 1990 Jani et al . (US ) ; Michael E . Jung, Los Angeles , 5 ,212 , 162 A 5 / 1993 Missel et al. CA (US ) ; Diana C . Marquez -Garban , 5 , 403 , 841 A 4 / 1995 Lang et al . 6 ,699 ,989 B1 * 3 / 2004 Shetty CO7D 215 / 56 Los Angeles, CA (US ) ; Gang Deng, 540 /474 Los Angeles, CA (US ) 7 , 285 ,681 B2 * 10 /2007 Moinet .. .. .. CO7D 295/ 215 564 /233 ( 73 ) Assignee : The Regents of the University of 7 ,671 , 019 B2 * 3 /2010 Tobia A61K 8 /44 California , Oaklnad , CA (US ) 514 / 1 . 1 8 , 853, 259 B2 10 /2014 Mylari Subject to any disclaimer, the term of this 2010 / 0087544 A1 4 / 2010 Kim et al. ( * ) Notice : 2011 /0196015 A1 8 / 2011 Kim et al . patent is extended or adjusted under 35 2011 / 0207810 Al 8 / 2011 Kim et al . U . S . C . 154 (b ) by 40 days. 2015 /0126518 Al 5 /2015 Kim et al . ( 21) Appl . No. : 14 /566 ,055 FOREIGN PATENT DOCUMENTS ( 22 ) Filed : Dec . 10 , 2014 WO WO - 96 /05309 A2 2 / 1996 WO WO - 96 /05309 A3 2 / 1996 (65 ) Prior Publication Data WO WO - 2011 /083998 A2 7 / 2011 WO WO - 2011 /083998 A3 7 / 2011 US 2015 /0158832 A1 Jun .
    [Show full text]
  • Thesis of Novel Anticancer Agents with Therapeutic Potential
    University of Bath PHD The synthesis of novel anticancer agents with therapeutic potential Ganeshapillai, Dharshini Award date: 2001 Awarding institution: University of Bath Link to publication Alternative formats If you require this document in an alternative format, please contact: [email protected] General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 08. Oct. 2021 THE SYNTHESIS OF NOVEL ANTICANCER AGENTS WITH THERAPEUTIC POTENTIAL Submitted by Dharshini Ganeshapillai for the degree of Doctor of Philosophy of the University of Bath 2001 COPYRIGHT Attention is drawn to the fact that the copyright of this thesis rests with its author. This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with its author and that no quotation from the thesis and no information derived from it may be published without the prior written consent of the author.
    [Show full text]
  • Aromatase Inhibitors As Potential Cancer Chemopreventives
    V Vol. 7, 65-78, Januar’, 1998 Cancer Epidemiology, Biomarkers & Prevention 65 Review Aromatase Inhibitors as Potential Cancer Chemopreventives Gary J. Kelloff,t Ronald A. Lubet, Ronald Lieberman, local estrogen production may be an alternative strategy, Karen Eisenhauer, Vernon E. Steele, James A. Crowell, as suggested by the discovery of a unique transcriptional Ernest T. Hawk, Charles W. Boone, and promoter of aromatase gene expression, 1.4, in breast Caroline C. Sigman adipose tissue. The development of drugs that target this Chemoprevention Branch, Division of Cancer Prevention and Control, promoter region may be possible. National Cancer Institute, Bethesda, Maryland 20852 1G. J. K., R. A. L., R. L.. V. E. S., J. A. C., E. T. H., C. W. B.l; and CCS Associates, Mountain View, Califomia 94043 1K. E., C. C. S.] Strategies in Development of Cancer Chemopreventive Agents This paper is the third in a series on strategies used by the Abstract Chemoprevention Branch of the National Cancer Institute to Epidemiological and experimental evidence strongly develop cancer chemoprevention drugs ( 1-3). One chemopre- supports a role for estrogens in the development and ventive strategy for hormone-dependent cancers is to interfere growth of breast tumors. A role for estrogen in prostate with the hormones that stimulate cellular proliferation in these neoplasia has also been postulated. Therefore, one tumors. Among the most important of these targets for inter- chemopreventive strategy for breast and prostate cancers vention are estrogen-responsive tumors. Estrogen production is to decrease estrogen production. This can be can be decreased by inhibiting aromatase, the enzyme cata- accomplished by inhibiting aromatase, the enzyme that lyzing the final, rate-limiting step in estrogen biosynthesis.
    [Show full text]
  • Drug and Hormone Interactions of Aromatase Inhibitors
    Endocrine-Related Cancer (1999) 6 181-185 Drug and hormone interactions of aromatase inhibitors M Dowsett Academic Department of Biochemistry, The Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK Abstract The clinical development of aromatase inhibitors has been largely confined to postmenopausal breast cancer patients and strongly guided by pharmacological data. Comparative oestrogen suppression has been helpful in circumstances in which at least one of the comparitors has caused substantially non-maximal aromatase inhibition. However, the triazole inhibitors, letrozole and anastrozole, and the steroidal inhibitor, exemestane, all cause >95% inhibition. Comparisons between these drugs there- fore require more sensitive approaches such as the direct measurement of enzyme activity by isotopic means. None of these three agents has significant effects on other endocrine pathways at its clinically applied doses. Pharmacokinetic analyses of the combination of tamoxifen and letrozole have revealed that these drugs interact, resulting in letrozole concentrations approximately 35-40% lower than when letrozole is used alone. Endocrine-Related Cancer (1999) 6 181-185 Introduction developed, with the most successful being the triazole group of inhibitors: letrozole, anastrozole, vorozole, and Over the past 20 years, a large number of aromatase YM511. The different mechanisms of interaction of the inhibitors have been studied in clinical pharmacological two types of inhibitors with the enzyme are well described trials and the results from these have contributed to the in the paper by Kao et al. (1996). clinical utilisation of the drugs, particularly in relation to the selection of dosage for widespread treatment. Some of these drugs are now accepted for use as the preferred Pharmacological effectiveness second-line agent (after tamoxifen) for advanced breast The degree to which an inhibitor reduces the activity of the cancer treatment and are also in large-scale trials for the aromatase enzyme can be measured in two ways: adjuvant treatment of breast cancer.
    [Show full text]